Pharmafile Logo
Pharmafocus logo
Advanced Search

JJ

Showing 15 posts of 221 posts found.

J&J image

J&J expects consent decree to extend through ‘most of 2013’

July 30, 2012
Manufacturing and Production FDA, J&J, JJ, McNeil, OTC, recall

Johnson & Johnson has said it expects the production capacity issues affecting two plants covered by a consent decree with …

News

New J&J chief still struggling with scandals

July 18, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Risperdal, Weldon, Xarelto, Zytiga

Johnson & Johnson has just released its Q2 figures showing sales fell back in the second quarter, a 3.5% growth …

Feature
FDA image

Janssen submits tuberculosis pill to FDA

July 4, 2012
Research and Development, Sales and Marketing Bedaquiline, FDA, J&J, JJ, Janssen, tuberculosis

Janssen has submitted its investigational tuberculosis pill bedaquiline for review by the FDA. The firm is seeking a licence for …

News
Xarelto image

FDA rejects licence extension for Xarelto

June 26, 2012
Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto

The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …

News
Risperdal image

J&J fined after ‘lying to patients for profit’

April 16, 2012
Medical Communications, Sales and Marketing J&J, JJ, Janssen, Risperdal, US

A US judge has slapped a $1.19 billion fine on Johnson & Johnson after it was found to be downplaying …

News

J&J unveils plans to boost Doxil supplies

April 10, 2012
Manufacturing and Production Ben Venue, Doxil, J&J, JJ, drug shortages

Johnson & Johnson is planning to transfer filling and packaging of Doxil to another supplier in an attempt to alleviate …

News

Synthes plant cited in FDA warning letter

March 8, 2012
Manufacturing and Production FDA, J&J, JJ, Synthes, manufacturing

The US FDA has sent a warning letter to surgical equipment manufacturer Synthes upbraiding it for deficiencies at a manufacturing …

News

Alex Gorsky named new chief executive of J&J

February 22, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Janssen, Weldon

Johnson & Johnson has named Alex Gorsky as its new chief executive, effective from 26 April. Gorsky was also nominated …

Appointment
Risperdal image

J&J to pay $1 billion for Risperdal charges

January 9, 2012
Sales and Marketing J&J, JJ, Janssen, Risperdal

Johnson & Johnson will pay more than $1 billion in the US to resolve a civil investigation into the marketing …

News

Janssen sets up new mental health social networking site

November 28, 2011
Medical Communications J&J, JJ, Janssen, NHS

Janssen and the NHS Confederation have established a new mental health social networking site. The service, which will be free …

News

Doxil shortages exacerbated as Ben Venue shutters plant

November 22, 2011
Manufacturing and Production Doxil, J&J, JJ, manufacturing and production

An acute shortage of Johnson & Johnson’s cancer drug Doxil (doxorubicin) in the US could get worse following a decision …

News

Xarelto succeeds in new study

November 14, 2011
Sales and Marketing Bayer, FDA, J&J, JJ, Xarelto

In a new study J&J and Bayer’s blood thinner Xarelto reduced deaths in patients after a heart attack, which could …

News
Merck & Co

Merck pulls out of J&J consumer venture

September 29, 2011
Sales and Marketing J&J, JJ, Merc & Co, OTC

Merck & Co has exited a joint venture with J&J, selling its stake in the J&J/Merck Consumer Pharmaceuticals business to …

News
Tylenol recall

J&J’s latest recall put down to new factor

August 19, 2011
Manufacturing and Production J&J, JJ, Tylenol, recalls

Yet another Johnson & Johnson recall has been announced, but this time the perpetrator doesn’t feature among the ‘usual suspects’. …

News

Triple regimen HIV pill gains approval

August 11, 2011
Gilead, HIV, J&J, JJ, Truvada

A new three-in-one pill Complera has been approved in the US as a first line treatment for HIV. Complera combines …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024